Nationwide Fund Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Nationwide Fund Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,040	Closed	-$188K	–	2346
2017 Q3	$188K	Buy	6,040 +1,672	+38%	+$50.3K	﹤0.01%	2668
2017 Q2	$138K	Buy	4,368 +1,206	+38%	+$29.7K	﹤0.01%	2769
2017 Q1	$72K	Sell	3,162 -500	-14%	-$12.3K	﹤0.01%	2918
2016 Q4	$80K	Hold	3,662	–	–	﹤0.01%	2930
2016 Q3	$97K	Hold	3,662	–	–	﹤0.01%	2901
2016 Q2	$72K	Buy	+3,662	New	+$71.2K	﹤0.01%	3019

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Nationwide Fund Advisors's RETA Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2017, closing a stake of 6,040 shares — an estimated $188K sold.

Nationwide Fund Advisors first reported a position in RETA in Q2 2016 and held it in 6 quarters. The position peaked at $188K in Q3 2017. 89 funds tracked by Wall St. Rank hold RETA as of Q4 2017.

Nationwide Fund Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 6,040 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2017, an estimated $188K.
Nationwide Fund Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 6 quarters.
Nationwide Fund Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $188K in Q3 2017.
89 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.